4612 Federal Register / Vol. 71, No.

18 / Friday, January 27, 2006 / Notices

investigation on the basis of two The authority for the Commission’s to issuing a regulation under 21 U.S.C.
settlement agreements. determination is contained in section 952(a)(2)(B) authorizing the importation
FOR FURTHER INFORMATION CONTACT: 337 of the Tariff Act of 1930, as of such a substance, provide
Steven Crabb, Esq., Office of the General amended (19 U.S.C. 1337), and in manufacturers holding registrations for
Counsel, U.S. International Trade sections 210.21(b), and 210.42 of the the bulk manufacture of the substance
Commission, 500 E Street, SW., Commission’s Rules of Practice and an opportunity for a hearing.
Washington, DC 20436, telephone (202) Procedure (19 CFR 210.21, 210.42). Therefore, in accordance with 21 CFR
708–5432. Copies of non-confidential By order of the Commission. 1301.34(a), this is notice that on August
documents filed in connection with this Issued: January 23, 2006. 17, 2005, Cerilliant Corporation, 811
investigation are or will be available for Marilyn R. Abbott, Paloma Drive, Suite A, Round Rock,
inspection during official business Secretary to the Commission. Texas 78664, made application by
hours (8:45 a.m. to 5:15 p.m.) in the renewal to the Drug Enforcement
[FR Doc. E6–1038 Filed 1–26–06; 8:45 am]
Office of the Secretary, U.S. Administration (DEA) to be registered as
BILLING CODE 7020–02–P
International Trade Commission, 500 E an importer of the basic classes of
Street, SW., Washington, DC 20436, controlled substances listed in Schedule
telephone (202) 205–2000. General I and II:
INTERNATIONAL TRADE
information concerning the Commission
COMMISSION
may also be obtained by accessing its Drug Schedule
Internet server (http://www.usitc.gov). [USITC SE–06–009]
The public record for this investigation Cathinone (1235) .......................... I
may be viewed on the Commission’s Sunshine Act Meeting Methcathinone (1237) .................. I
N-Ethylamphetamine (1475) ........ I
electronic docket (EDIS) at http://
AGENCY HOLDING THE MEETING: United Gamma hydroxybutyric acid I
edis.usitc.gov. Hearing-impaired (2010).
States International Trade Commission.
persons are advised that information on Ibogaine (7260) ............................ I
TIME AND DATE: February 8, 2006 at 11
this matter can be obtained by Tetrahydrocannabinols (7370) ..... I
contacting the Commission’s TDD a.m. Mescaline (7381) .......................... I
terminal on (202) 205–1810. PLACE: Room 101, 500 E Street, SW., 4-Bromo-2,5- I
SUPPLEMENTARY INFORMATION: This
Washington, DC 20436, Telephone: dimethoxyamphetamine (7391).
investigation was instituted by the (202) 205–2000. 4-Bromo-2,5- I
STATUS: Open to the public. dimethoxyphenethylamine
Commission based on a complaint filed (7392).
by BenQ Corporation of Taiwan and MATTERS TO BE CONSIDERED:
4-Methyl-2,5- I
BenQ America Corporation of Irvine, 1. Agenda for future meetings: none. dimethoxyamphetamine (7395).
California. See 70 FR 35453 (June 20, 2. Minutes. 2,5-Dimethoxyamphetamine I
2005). The complaint alleged violations 3. Ratification List. (7396).
of section 337 of the Tariff Act of 1930 4. Inv. No. 731–TA–1089 (Final)(Certain 3,4-Methylenedioxyamphetamine I
in the importation into the United Orange Juice from Brazil)—briefing (7400).
States, the sale for importation, and the and vote. (The Commission is 3,4- I
currently scheduled to transmit its Methylenedioxymethamphetam-
sale in the United States after
determination and Commissioners’ ine (7404).
importation of certain DVD/CD players 3,4- I
and recorders, color television receivers opinions to the Secretary of
Methylenedioxymethamphetam-
and monitors, and components thereof Commerce on or before February 21,
ine (7405).
by reason of infringement of claims 7– 2006.) 4-Methoxyamphetamine (7411) ... I
11 and 13–15 of U.S. Patent No. 5. Outstanding action jackets: None. Psilocybin (7437) .......................... I
5,270,821, and claims 1, 2, 4, and 5 of In accordance with Commission Psilocyn (7438) ............................. I
U.S. Patent No. 6,683,842. The policy, subject matter listed above, not Etorphine (9056) ........................... I
complaint named Thomson Inc. of disposed of at the scheduled meeting, Heroin (9200) ............................... I
Indianapolis, Indiana as the respondent. may be carried over to the agenda of the Pholcodine (9314) ........................ I
following meeting. Amphetamine (1100) .................... II
On December 9, 2005, the private Methamphetamine (1105) ............ II
parties filed a joint motion to terminate Issued: January 25, 2006. Methylphenidate (1724) ................ II
the investigation on the basis of two By order of the Commission. Amobarbital (2125) ....................... II
settlement agreements. On December 14, Marilyn R. Abbott, Pentobarbital (2270) ..................... II
2005, the Commission investigative Cocaine (9041) ............................. II
Secretary to the Commission.
attorney filed a response in support of Codeine (9050) ............................. II
[FR Doc. 06–866 Filed 1–25–06; 3:48 pm] Dihydrocodeine (9120) ................. II
the parties’ joint motion to terminate the
investigation. BILLING CODE 7020–02–P Oxycodone (9143) ........................ II
On December 21, 2005, the ALJ issued Hydromorphone (9150) ................ II
Benzoylecgonine (9180) ............... II
an ID (Order No. 16) granting the joint
DEPARTMENT OF JUSTICE Ethylmorphine (9190) ................... II
motion to terminate the investigation on Meperidine (9230) ........................ II
the basis of the settlement agreements. Methadone (9250) ........................ II
The ALJ found no indication that such Drug Enforcement Administration
Dextropropoxyphene, bulk (non- II
termination of the investigation would Importer of Controlled Substances; dosage forms) (9273).
adversely impact the public interest. No Notice of Application Morphine (9300) ........................... II
party filed a petition to review the Thebaine (9333) ........................... II
rmajette on PROD1PC67 with NOTICES

subject ID. Pursuant to 21 U.S.C. 958(i), the Levo-alphacetylmethadol (9648) .. II

The Commission has determined not Attorney General shall, prior to issuing Oxymorphone (9652) ................... II
to review the ALJ’s ID. Accordingly, the a registration under this Section to a
above-referenced investigation is hereby bulk manufacturer of a controlled The company plans to import small
terminated. substance in Schedule I or II and prior quantities of the listed controlled

VerDate Aug<31>2005 15:17 Jan 26, 2006 Jkt 208001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\27JAN1.SGM 27JAN1
 Federal Register / Vol. 71, No. 18 / Friday, January 27, 2006 / Notices
substances for the manufacture of
analytical reference standards.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than February 27, 2006.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
Schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: January 20, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–1023 Filed 1–26–06; 8:45 am]
BILLING CODE 4410–09–P
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
Meetings of Humanities Panel
AGENCY: The National Endowment for
the Humanities.
ACTION: Notice of meetings.
SUMMARY: Pursuant to the provisions of
rmajette on PROD1PC67 with NOTICES
the Federal Advisory Committee Act
(Public Law 92–463, as amended),
notice is hereby given that the following
meetings of Humanities Panels will be
held at the Old Post Office, 1100
VerDate Aug<31>2005 15:17 Jan 26, 2006 Jkt 208001
Pennsylvania Avenue, NW.,
Washington, DC 20506.
FOR FURTHER INFORMATION CONTACT:
Michael McDonald, Advisory
Committee Management Officer,
National Endowment for the
Humanities, Washington, DC 20506;
telephone (202) 606–8322. Hearing-
impaired individuals are advised that
information on this matter may be
obtained by contacting the
Endowment’s TDD terminal on (202)
606–8282.
SUPPLEMENTARY INFORMATION: The
proposed meetings are for the purpose
of panel review, discussion, evaluation
and recommendation on applications
for financial assistance under the
National Foundation on the Arts and the
Humanities Act of 1965, as amended,
including discussion of information
given in confidence to the agency by the
grant applicants. Because the proposed
meetings will consider information that
is likely to disclose trade secrets and
commercial or financial information
obtained from a person and privileged
or confidential and/or information of a
personal nature the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy, pursuant
to authority granted me by the
Chairman’s Delegation of Authority to
Close Advisory Committee meetings,
dated July 19, 1993, I have determined
that these meetings will be closed to the
public pursuant to subsections (c) (4),
and (6) of section 552b of Title 5, United
States Code.
1. Date: February 1, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Scholarly Editions in
American and British Literature and
Cultural History, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
2. Date: February 2, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in American Studies, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
3. Date: February 2, 2006.
Time: 8:30 a.m. to 5:30 p.m.
Room: 415.
Program: This meeting will review
applications for Colleges and
Universities, submitted to the Office of
Challenge Grants at the November 1,
2005 deadline.
4. Date: February 3, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 E:\FR\FM\27JAN1.SGM
4613
Program: This meeting will review
applications for Scholarly Editions in
American History, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
5. Date: February 6, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in Literature and the Arts, submitted to
the Division of Research Programs at the
November 1, 2005 deadline.
6. Date: February 7, 2006.
Time: 8:30 a.m. to 5:30 p.m.
Room: 415.
Program: This meeting will review
applications for History Organizations,
submitted to the Office of Challenge
Grants at the November 1, 2005
deadline.
7. Date: February 8, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Scholarly Editions in
Classical, Medieval, and Early Modern
Texts, submitted to the Division of
Research Programs at the November 1,
2005 deadline.
8. Date: February 9, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in European Studies, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
9. Date: February 10, 2006.
Time: 8:30 a.m. to 5 p.m.
Room: 315.
Program: This meeting will review
applications for Collaborative Research
in Africa and Asia, submitted to the
Division of Research Programs at the
November 1, 2005 deadline.
10. Date: February 28, 2006.
Time: 9:00 a.m. to 5 p.m.
Room: 415.
Program: This meeting will review
applications for Stabilization I,
submitted to the Division of
Preservation and Access at the October
1, 2005 deadline.
Michael McDonald,
Advisory Committee Management Officer.
[FR Doc. E6–1031 Filed 1–26–06; 8:45 am]
BILLING CODE 7536–01–P
NUCLEAR REGULATORY
COMMISSION
Request To Amend a License for the
Export of Radioactive Waste
Pursuant to 10 CFR 110.70(b)(4)
‘‘Public notice of receipt of an
27JAN1